DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Inhaled Tobramycin

To Patients

To Patients

Therapeutic Approach

Anti-Infective

TOBI® and  BETHKIS® are aerosolized forms of the antibiotic tobramycin, which is used to treat people with CF who are chronically infected with Pseudomonas aeruginosa. 

Status

In the US, the FDA approved TOBI® in 1997. 
In Australia,TOBI® is approved.

Sponsor

In the US, the TOBI® program was sponsored by Novartis Pharmaceuticals and funded by Cystic Fibrosis Foundation Therapeutics (CFFT). The program was conducted within CFFT's Therapeutics Development Network.

Contact us about Inhaled Tobramycin >